All Stories

  1. Sex Differences in Cancer-Associated Thrombosis
  2. Artificial Intelligence for Automated Detection of Joint Bleeding via Ultrasound in Hemophilia: Advancing Standardization
  3. Correction to: Usefulness of Cone-Beam Computed Tomography and Automatic Vessel Detection Software in Embolization for Osteoarthritis
  4. IFNAR2 p.F8S Variant Associates with Severe COVID-19 and Adaptive Immune Cell Activation Modulation
  5. Usefulness of Cone-Beam Computed Tomography and Automatic Vessel Detection Software in Embolization for Osteoarthritis
  6. Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study
  7. Thickening of the Intramuscular Fascia of the Iliacus Muscle as Evidence of Myofascial Pathology: A New Hip Pain Syndrome
  8. Interactive Guidance for Self-Acquisition of Ultrasound Images by Hemophilic Patients
  9. Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): Recommendations from Italian scientific societies, patient associations and regulators
  10. Bridging the gap: Time to integrate sex and gender differences into research and clinical practice for improved health outcomes
  11. Gene therapy in hemophilia: the dawn of a new era
  12. Exploring the Impact of Sex and Gender in Brain Function: Implications and Considerations
  13. Fibro-adhesive Bursitis: A Novel Sonographic Finding in Adhesive Capsulitis Patients and a Proposal of Management
  14. Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life
  15. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology
  16. Bleeding and thrombotic events and intensity of heparin therapy in the two first waves of COVID-19
  17. Assessing joint health in haemophilia patients: The combined value of physical examination and ultrasound imaging
  18. Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis
  19. Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome
  20. Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A
  21. Joint Dysfunction as a Cause of Spontaneous Subclinical Bleeding in Infants with Hemophilia
  22. Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study
  23. Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy.
  24. Nailfold Videocapillaroscopic Alterations as Markers of Microangiopathy in COVID-19 Patients
  25. Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination
  26. Updates on Novel Non-Replacement Drugs for Hemophilia
  27. Lung Ultrasound Findings and Endothelial Perturbation in a COVID-19 Low-Intensity Care Unit
  28. Successful Chemical Synovectomy in a Patient with Acquired von Willebrand Syndrome with Chronic Synovitis Due to Recurrent Knee Hemarthrosis: A Case Report
  29. Play4Physio: Supporting Physical Therapy of Children with Hemophilia
  30. A Response to: Letter to the Editor Regarding Ultrasound Features of Adhesive Capsulitis
  31. Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy
  32. Ultrasound Features of Adhesive Capsulitis
  33. Hemophilic arthropathy: Current knowledge and future perspectives
  34. The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians
  35. Hemostatic alterations in COVID-19
  36. Inflammatory interactions between degenerated intervertebral discs and microglia: implication of sphingosine‐1‐phosphate signalling
  37. Anti-atherogenic Modification of Serum Lipoprotein Function in Patients with Rheumatoid Arthritis after Tocilizumab Treatment, a Pilot Study
  38. Hereditary Deficiency of the Second Component of Complement: Early Diagnosis and 21-Year Follow-Up of a Family
  39. IFI16 and Anti-IFI16 as Novel Biomarkers for Sjoegren’s Syndrome: Preliminary Data
  40. Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
  41. Fibromyalgia and Shoulder Surgery: A Systematic Review and a Critical Appraisal of the Literature
  42. Identification of a Shared Microbiomic and Metabolomic Profile in Systemic Autoimmune Diseases
  43. Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report
  44. P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus
  45. Vitamin D and Anti-Phospholipid Antibody Syndrome: A Comprehensive Review
  46. Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases
  47. Total Joint Arthroplasty in Patients with Inflammatory Rheumatic Diseases
  48. The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts
  49. Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview
  50. Detection of early endothelial damage in patients with Raynaud's phenomenon
  51. Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis
  52. Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review
  53. Modulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids
  54. Understanding cardiovascular risk in rheumatoid arthritis: Still a long way to go
  55. Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis
  56. Health-Related Quality of Life in Systemic Sclerosis: Feasibility and Construct Validity of Eq-5d
  57. The Adipose Mesenchymal Stem Cell Secretome Inhibits Inflammatory Responses of Microglia: Evidence for an Involvement of Sphingosine-1-Phosphate Signalling
  58. Smac127 Has Proapoptotic and Anti-Inflammatory Effects on Rheumatoid Arthritis Fibroblast-Like Synoviocytes
  59. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study
  60. Mesenchymal stem cells: potential for therapy and treatment of chronic non-healing skin wounds
  61. Corrigendum to ‘Autoantibodies to coagulation factors: From pathophysiology to diagnosis and therapy’ [Autoimmun Rev 13/1 (2014) p.40–48]
  62. AB1085 Empirical Approach to Investigate Raynaud's Phenomenon: The Pearl Study
  63. OP0221 Nailfold Capillaroscopy Patterns in Adulthood are Similar in Patients with Juvenile and Adult-Onset Systemic Sclerosis: A Eustar Case-Control Study
  64. Sparing effect of hemiplegia on skin fibrosis and microvascular involvement: Reports of two cases of systemic sclerosis and review of the literature
  65. Gene Expression Profile Analysis of Human Mesenchymal Stem Cells from Herniated and Degenerated Intervertebral Discs Reveals Different Expression of Osteopontin
  66. Choroidal impairment and macular thinning in patients with systemic sclerosis: The acute study
  67. Uniphasic Blanching of the Fingers, Abnormal Capillaroscopy in Nonsymptomatic Digits, and Autoantibodies: Expanding Options to Increase the Level of Suspicion of Connective Tissue Diseases beyond the Classification of Raynaud’s Phenomenon
  68. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome
  69. AB1013 Systemic Sclerosis and Myositis Extractable Nuclear Antigen (ENA) Analysis: Profile of A Cohort of Subjects with Isolated Raynaud's Phenomenon
  70. Authors’ Reply to Verdelli et al.: There Is No Knowledge Without Experience
  71. Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk
  72. Autoantibodies to coagulation factors: From pathophysiology to diagnosis and therapy
  73. Rheumatoid Factors
  74. Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon?
  75. Choosing treatment options for patients with relapsed/refractory multiple myeloma
  76. Is it safe to withdraw etanercept in established rheumatoid arthritis after low disease activity achievement?
  77. Tocilizumab Monotherapy in a Patient with Rheumatoid Arthritis and Iatrogenic Kaposi Sarcoma
  78. Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria
  79. A systematic overview on the use and relevance of capillaroscopy in systemic sclerosis
  80. Nailfold capillary patterns in healthy subjects: A real issue in capillaroscopy
  81. Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients
  82. SAT0214 Reliability and Validity of the Italian Version of the Ucla-Scleroderma Clinical Trial Consortium-Gastrointestinal Tract Instrument in Patients with Systemic Sclerosis
  83. AB0830 Role of anti-IFI16 antibodies and NT-PROBNP as candidate biomarkers in systemic sclerosis
  84. FRI0402 Vascular changes in choroid plexus in patients with raynaud’s phenomenon suspected secondary to a connective tissue disease
  85. FRI0403 How early starts increased collagen synthesis in systemic sclerosis?
  86. SAT0401 The nailfold capillary patterns in healthy subjects: A two center study
  87. Pre-conceptional exposure to rituximab: comment on the article by Ojeda-Uribe et al.
  88. An overlooked cause of back pain and stiffness
  89. Current and Emerging Treatment Options for Patients with Relapsed Myeloma
  90. Rheumatoid Factors: Clinical Applications
  91. Rheumatoid Nodules Predating Seroconversion and Rheumatoid Arthritis: An Uncommon Case Report
  92. The Role of Ultrasonography in the Assessment of Skeletal Hand Involvement in Systemic Sclerosis
  93. Nailfold capillaroscopic report: qualitative and quantitative methods
  94. Health related quality of life assessment in patients with systemic sclerosis
  95. Cutting-Edge Issues in Coronary Disease and the Primary Antiphospholipid Syndrome
  96. Updating on the pathogenesis of systemic lupus erythematosus
  97. Hand impairment in systemic sclerosis: association of different hand indices with organ involvement
  98. Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis
  99. Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy
  100. Feasibility of Different Capillaroscopic Measures for Identifying Nailfold Microvascular Alterations
  101. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (Prognostic Index for Nailfold Capillaroscopic Examination)
  102. Reliability and validity of the Italian version of the hand functional disability scale in patients with systemic sclerosis